Clinical Research Directory
Browse clinical research sites, groups, and studies.
VA as Maintenance Therapy Post Allo-HSCT in MDS and AML
Sponsor: Navy General Hospital, Beijing
Summary
The goal of this phase 2 trial is to test the safety and efficacy of Venetoclax combined with Azacytidine as Maintenance Therapy post Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Official title: Venetoclax Combined With Azacytidine as Maintenance Therapy Post Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Key Details
Gender
All
Age Range
16 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-09
Completion Date
2030-09
Last Updated
2024-10-01
Healthy Volunteers
No
Conditions
Interventions
Venetoclax combined with Azacytidine
Patients were treated by venetoclax and azacytidine: Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5.